Treating elderly patients with hormone sensitive breast cancer: What do the data show?

Cancer Treatment Reviews

Volumn 35, Issue 1, 2009, Pages 47-56

  Balducci, L ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Aromatase inhibitors; Breast cancer; Elderly; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; FLUOXETINE; LETROZOLE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN;

ADJUVANT THERAPY; ARTHRALGIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER RELAPSE; CARDIOVASCULAR DISEASE; CARPAL TUNNEL SYNDROME; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMORBIDITY; CYSTITIS; DEPRESSION; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; ESTROGEN BLOOD LEVEL; FRACTURE; GERIATRIC ASSESSMENT; GERIATRIC PATIENT; GYNECOLOGIC DISEASE; HAIR LOSS; HEART DISEASE; HEART INFARCTION; HOT FLUSH; HUMAN; INDIGESTION; LIFE EXPECTANCY; MASTALGIA; MASTECTOMY; MONOTHERAPY; MUSCLE CRAMP; MUSCULOSKELETAL PAIN; NAUSEA; NIGHT SWEAT; OSTEOPOROSIS; OVERALL SURVIVAL; PARESTHESIA; PARTIAL MASTECTOMY; PATIENT COMPLIANCE; POSTMENOPAUSE; PROGNOSIS; PRURITUS; REVIEW; SENESCENCE; SOMNOLENCE; THROMBOEMBOLISM; THROMBOPHLEBITIS; UTERUS MYOMA; VAGINA BLEEDING; VAGINA DISCHARGE; VERTIGO;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT;

EID: 58549084352     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2008.08.001     Document Type: Review

References (60)

1. Muss H.B. Adjuvant treatment of elderly breast cancer patients. Breast 16 Suppl. 2 (2007) S159-S165
2. Ries LAG, Melbert D, Krapcho M, et al., editors. SEER cancer statistics review, 1975-2004. Bethesda: National Cancer Institute.
3. Howell A., Cuzick J., Baum M., et al., ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
4. Thürlimann B., Keshaviah A., Coates A.S., et al. Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. New Engl J Med 353 (2005) 2747-2757
5. Coombes R.C., Kilburn L.S., Snowdon C.F., et al. Intergroup Exemestane Study Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369 (2007) 559-570
6. Erratum in:. Coombes R.C., Kilburn L.S., Snowdon C.F., et al. Lancet 369 (2007) 906
7. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., and Piccart M.J. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA. 17. J Natl Cancer Inst 97 (2005) 1262-1271
8. Winer E.P., Hudis C., Burstein H.J., et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23 (2005) 619-629
9. Balducci L., and Ershler W.B. Cancer and ageing: a nexus at several levels. Nat Rev Cancer 5 (2005) 655-662
10. Jagger C., Matthews R., Matthews F., et al. The burden of diseases on disability-free life expectancy in later life. J Gerontol A Biol Sci Med Sci 62 (2007) 408-414
11. Ethgen O., Gillain D., Gillet P., et al. Age- and sex-stratified prevalence of physical disabilities and handicap in the general population. Aging Clin Exp Res 16 (2004) 389-397
12. MedicineNet.com. What are the complications and effects of menopause on chronic medical conditions? [Accessed 14.04.2008].
13. The Cleveland Clinic. Osteoporosis and you: protecting your bones. [Accessed 14.04.2008].
14. Braithwaite R.S., Col N.F., and Wong J.B. Estimating hip fracture morbidity, mortality and costs. J Am Geriatr Soc 51 (2003) 364-370
15. American Heart Association. Heart disease and stroke statistics - 2006 Update. Dallas: American Heart Association; 2006.
16. Lee S.J., Lindquist K., Segal M.R., and Covinsky K.E. Development and validation of a prognostic index for 4-year mortality in older adults. JAMA 295 (2006) 801-808
17. Cohen H.J., Harris T., and Pieper C.F. Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. Am J Med 114 (2003) 180-187
18. Ralph D.A., Zhao L.P., Aston C.E., et al. Age-specific association of steroid hormone pathway gene polymorphisms with breast cancer risk. Cancer 109 (2007) 1940-1948
19. Anisimov V.N. Biology of aging and cancer. Cancer Control 14 (2007) 23-31
20. Ershler W.B. The influence of advanced age on cancer occurrence and growth. Cancer Treat Res 124 (2005) 75-87
21. Campisi J., and d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 8 (2007) 729-740
22. Opatrny L., Dell'Aniello S., Assouline S., and Suissa S. Hormone replacement therapy use and variations in the risk of breast cancer. BJOG 115 (2008) 169-175 [Discussion 175]
23. Satariano W.A., and Ragland D.R. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 120 (1994) 104-110
24. Rao V.S., Garimella V., Hwang M., and Drew P.J. Management of early breast cancer in the elderly. Int J Cancer 120 (2007) 1155-1160
25. Beghe C., and Lodovico B. Cancer and aging. In: John Pathy M.A., Sinclair A.J., and Morley J.E. (Eds). Principles and practice of geriatric medicine. 4th ed. vol. 2 (2006), Wiley Publishers, Hoboken, NJ 1507-1517
26. Okanami Y., Iwase T., Kimura K., et al. Tumor biology of breast carcinoma in elderly women: Comparison between elderly and young postmenopausal women. Breast Cancer Res Treat 100 Suppl. 1 (2007) S257 [Abstract 6032]
27. Daidone M.G., Coradini D., Martelli G., and Veneroni S. Primary breast cancer in elderly women: biological profile and relation with clinical outcome. Crit Rev Oncol Hematol 45 (2003) 313-325
28. Grann V.R., Troxel A.B., Zojwalla N.J., Jacobson J.S., Hershman D., and Neugut A.I. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer 103 (2005) 2241-2251
29. Pierga J.Y., Girre V., Laurence V., et al. Institut Curie Breast Cancer Study Group. Characteristics and outcome of 1755 operable breast cancers in women over 70 years of age. Breast 13 (2004) 369-375
30. Bouchardy C., Rapiti E., Fioretta G., et al. Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol 21 (2003) 3580-3587
31. Owusu C., Buist D., Field T., Lash T., Thwin S., and Silliman R. Tamoxifen discontinuance among women aged 65 years and older with estrogen receptor positive breast cancer. J Clin Oncol 24 18S (2006) 39s [Abstract 648]
32. Braithwaite R.S., Chlebowski R.T., Lau J., George S., Hess R., and Col N.F. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 18 (2003) 937-947
33. Hind D., Wyld L., and Reed M.W. Surgery, with or without tamoxifen, vs tamoxifen alone for older women with operable breast cancer: Cochrane review. Br J Cancer 96 (2007) 1025-1029
34. Arimidex® (Anastrozole) package insert. Astra Zeneca Pharmaceuticals LP: Wilmington, Delaware; 2005.
35. Kemeny M.M., Peterson B.L., Kornblith A.B., et al. Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol 21 (2003) 2268-2275
36. Erratum in:. Kemeny M.M., Peterson B.L., Kornblith A.B., et al. Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol 22 (2004) 4811
37. Hutchins L.F., Unger J.M., Crowley J.J., Coltman Jr. C.A., and Albain K.S. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. New Engl J Med 341 (1999) 2061-2067
38. Crivellari D., Sun Z., Coates A.S., et al. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol (2008) [Epub ahead of print]
39. Extermann M., Balducci L., and Lyman G.H. What threshold for adjuvant therapy in older breast cancer patients?. J Clin Oncol 18 (2000) 1709-1717
40. Lash T.L., Silliman R.A., Guadagnoli E., and Mor V. The effect of less than definitive care on breast carcinoma recurrence and mortality. Cancer 89 (2000) 1739-1747
41. Rao V.S., Jameel J.K., Mahapatra T.K., McManus P.L., Fox J.N., and Drew P.J. Surgery is associated with lower morbidity and longer survival in elderly breast cancer patients over 80. Breast J 13 (2007) 368-373
42. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-17.
43. Hind D., Wyld L., Beverley C.B., and Reed M.W. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Database Syst Rev 1 (2006) CD004272
44. Words to Live By. Matria Healthcare. . [Accessed 14.04.2008].
45. Soudry A., Dufouil C., Ritchie K., Dartigues J.F., Tzourio C., and Alpérovitch A. Factors associated with changes in antidepressant use in a community-dwelling elderly cohort: the Three-City Study. Eur J Clin Pharmacol 64 (2008) 51-59
46. Cazzaniga M., Mustacchi G., Pronzato P., De Matteis A., Di Costanzo F., Floriani I., et al. Adjuvant treatment of early breast cancer: do the St Gallen recommendations influence clinical practice? Results from the NORA study. Ann Oncol 18 (2007) 1976-1980
47. Aiello E.J., Buist D.S., Wagner E.H., et al. Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network. Breast Cancer Res Treat 107 (2008) 397-403
48. Muss H.B., Tu D., Ingle J.N., et al. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG Intergroup Trial MA.17. J Clin Oncol (2008) [Epub ahead of print]
49. Forbes J.F., Cuzick J., Buzdar A., Howell A., Tobias J.S., Baum M., et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9 (2008) 45-53
50. Monnier A.M. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer. Expert Rev Anticancer Ther 7 (2007) 627-634
51. Coombes R.C., Hall E., Gibson L.J., et al. Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. New Engl J Med 350 (2004) 1081-1092
52. Goss P.E., Ingle J.N., Martino S., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. New Engl J Med 349 (2003) 1793-1802
53. Whelan T.J., Goss P.E., Ingle J.N., et al. Assessment of quality of life in MA 17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 23 (2005) 6931-6940
54. Chapman J.A., Meng D., Shepherd L., et al. Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J Natl Cancer Inst 100 (2008) 252-260
55. Biganzoli L., Licitra S., Claudino W., Pestrin M., and Leo A.D. Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients - a jungle?. Eur J Cancer 43 (2007) 2270-2278
56. Wildiers H., Kunkler I., Biganzoli L., et al. International Society of Geriatric Oncology Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol 8 (2007) 1101-1115
57. Monnier A., Sakek N., and Aladen S. Comparing AI cardiovascular safety data: trial comparators and outcomes. Ann Oncol 17 Suppl. 9 (2006) ix100 poster 266P
58. Brufsky A., Bosserman L., Caradonna R., et al. The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the Z-FAST study 36-month follow-up. Breast Cancer Res Treat 100 Suppl. 1 (2007) S8-S9 [Abstract 27]
59. Durbecq V., Ameye L., Veys I., Paesmans M., Desmedt C., Sirtaine N., et al. Significant proportion of elderly patients develop hormone-dependant "luminal-B" tumors associated with aggressive characteristics. Crit Rev Oncol Hematol 67 1 (2008) 80-92
60. Stearns V., Hayes D.F., Jin Y., Ullmer L., Nguyen A., Storniolo A.M., et al. The effect of CYP 2D6 genotype and CYP2D6 inhibitors on tamoxifen. Proc Am Soc Clin Oncol 22 4S (2004) 508